Each platform, or "work cell," which dispenses highly precise volumes of specialized reagents for detecting COVID-19 antibodies, can enable production of one m point-of-care tests per week.
BioDot is operating 7 days a week to meet demand from global diagnostics manufacturers, including contract development manufacturing organizations.
Worldwide, more than 50 companies are producing or developing COVID-19 antibody tests using BioDot technology.
Lateral flow tests for COVID-19 can detect virus antibodies in blood (IgG, IgM or both).
A patient's blood sample is placed onto a pad on the test device, onto which a BioDot work cell has previously dispensed a specific sequence of reagents and controls.
While clinicians wait, roughly 15 minutes, antibodies against SARS-CoV-2 in the sample will attach to test lines and present a positive or negative result visually or through a reader.
BioDot's automated dispensing platforms are used by diagnostics manufacturers to produce high-quality COVID-19 tests rapidly and at a scale, and these companies are responsible for regulatory approvals and distribution to the point of care.
BioDot is a provider of automated, ultralow-volume, non-contact fluid dispensing platforms for R and D applications and commercial-scale manufacturing across diagnostics and life sciences, medical products and applied industrial markets.
Its technologies are integral to production of point-of-care diagnostics for infectious diseases, allergy tests and diabetes maintenance as well as veterinary medicine and environmental applications.
BioDot, founded in 1994, is based in Irvine, Calif. and has international offices in Europe and Asia.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults